FDA Considers Loosening Naproxen's CV WarningFDA Considers Loosening Naproxen's CV Warning

The FDA says the data "suggest that naproxen is not associated with an increased risk of cardiovascular thrombotic events" and recommends changing the label to reflect this lower risk. Heartwire
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Cardiology News Source Type: news